Condition: Non-Small Cell Lung Cancer · Epidermal Growth Factor Receptor · Sponsor: Pusan National University Hospital
This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.
This description comes directly from the study's public registry record.
Mi-Hyun Kim · 82-51-240-7845 · mihyunkim@pusan.ac.kr
Soo Han Kim · 82-51-240-7845 · kshyjt1004@gmail.com
Always discuss trial participation with your own doctor first.
| Pusan National University Hospital | Busan, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07073365